Войти в систему Зарегистрироваться бесплатно

Kazia Therapeutics Валовая прибыль

Что обозначает Валовая прибыль в Kazia Therapeutics?

Валовая прибыль Kazia Therapeutics Limited является 100.00%

Какое определение для Валовая прибыль?



Валовая прибыль - это разница между доходом и стоимостью проданных товаров, разделенная на доход и выраженная в процентах.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Валовая прибыль компаний в Health Care сектор на ASX по сравнению с Kazia Therapeutics

Что делает Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Компании с валовая прибыль похож на Kazia Therapeutics